NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/17/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization312.8 mln
Float53.28 mln
Earnings Date11/16/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
54.3
Highly suspicious
1-Year Forecast
18.86
Transformational upside
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.16
Very low leverage
Pre-Tax Margin
-307%
Severely loss-making
Business Description
Abeona Therapeutics is a US-based biopharmaceutical company focused on developing gene and cell therapies for serious, life-threatening conditions. Its leading product, ZEVASKYN, is designed to treat recessive dystrophic epidermolysis bullosa, a severe skin disorder, while its pipeline includes additional therapies targeting rare eye diseases such as X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. Founded in 1974 and headquartered in Cleveland, Ohio, the company also advances a broader gene therapy platform aimed at addressing other difficult-to-treat conditions.
